<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923609</url>
  </required_header>
  <id_info>
    <org_study_id>CELLpEF</org_study_id>
    <nct_id>NCT02923609</nct_id>
  </id_info>
  <brief_title>Cell Therapy in HFpEF</brief_title>
  <acronym>CELLpEF</acronym>
  <official_title>A PILOT TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate safety and efficacy of transendocardial&#xD;
      CD34+ cell therapy in patients with HFpEF by evaluating changes in myocardial structure and&#xD;
      function, patient exercise capacity and clinical outcome.&#xD;
&#xD;
      The safety end-points include serious adverse events (SAEs), defined as any serious event&#xD;
      that may result in persistent or significant disability or incapacity and included death,&#xD;
      heart transplantation, sustained ventricular arrhythmia (ventricular tachycardia or&#xD;
      ventricular fibrillation), and heart failure exacerbation requiring hospitalization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In all patients, peripheral blood stem cells will be mobilized by daily subcutaneous&#xD;
      injections of G-CSF (10 mcg/kg, divided b.i.d) for 5 days. Peripheral blood stem cells will&#xD;
      then be collected with Miltenyi cell separator (Miltenyi Biotech, Germany) and the magnetic&#xD;
      cell separator Isolex 300i (Nexell Therapeutics Inc., California, USA) will be used for the&#xD;
      immunomagnetic positive selection of the CD34+ cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study is designed in a prospective crossover fashion. In Phase 1 of the study, all patients are treated with optimization of medical therapy for 6 months. Thereafter, all patients cross over to Phase 2 of the study, where they receive transendocardial CD34+ cell therapy. Follow-up of Phase 2 lasts for 6 months. At the time of enrollment (6 months before cell therapy), at time of cell therapy, and 6 months thereafter we will perform detailed clinical evaluation, laboratory assays, echocardiography, 6-minute walk test, and measure plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The echocardiographer will be blinded for the timing of echocardiographic recordings.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular filling pressures (E/e') assessed by echocardiography</measure>
    <time_frame>Baseline, 6 months and 1 year</time_frame>
    <description>The E/e' ratio will be calculated from early transmitral velocity divided by peak left ventricular relaxation velocity for estimation of the left ventricular filling pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in exercise capacity</measure>
    <time_frame>Baseline, 6 months and 1 year</time_frame>
    <description>6-minute walk test will be performed by a blinded observer according to the standard protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP levels</measure>
    <time_frame>Baseline, 6 months and 1 year</time_frame>
    <description>NT-proBNP assays will be performed at a central independent laboratory, blinded to the patient's clinical data using a commercially available kit (Roche Diagnostics, Mannheim, Germany).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic strain</measure>
    <time_frame>Baseline, 6 months and 1 year</time_frame>
    <description>Left ventricular longitudinal strains will be analyzed by speckle tracking echocardiography from apical four-chamber, two-chamber, and long-axis views.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic dysfunction grade</measure>
    <time_frame>Baseline, 6 months and 1 year</time_frame>
    <description>Diastolic dysfunction will be graded according based on E/A ratio and left atrial pressure estimation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>SC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 1 of the study, all patients will be treated with optimization of medical therapy for 6 months. Thereafter, all patients will cros over to Phase 2 of the study, where they will receive transendocardial CD34+ cell therapy. Follow-up of Phase 2 will last for 6 months. At the time of enrollment (6 months before cell therapy), at time of cell therapy, and 6 months thereafter we will perform detailed clinical evaluation, laboratory assays, echocardiography, 6-minute walk test, and measure plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell Therapy</intervention_name>
    <description>Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStarÂ® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.</description>
    <arm_group_label>SC Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preserved left ventricular systolic function on echocardiography (LVEF&gt;50%)&#xD;
&#xD;
          -  Evidence of diastolic dysfunction by echocardiography (E/e'&gt;15)&#xD;
&#xD;
          -  Symptoms of heart failure&#xD;
&#xD;
          -  NT-proBNP levels &gt;300 pg/ml&#xD;
&#xD;
          -  absence of permanent atrial fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute multi-organ failure&#xD;
&#xD;
          -  history of any malignant disease within 5 years&#xD;
&#xD;
          -  diminished functional capacity due to non-cardiac co-morbidities (COPD, PAOD, morbid&#xD;
             obesity)&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bojan Vrtovec, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, UMC Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bojan Vrtovec, MD, PhD</last_name>
    <phone>+3861 522 1157</phone>
    <email>bojan.vrtovec@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gregor Poglajen, MD, PhD</last_name>
    <phone>+3861 522 1148</phone>
    <email>gregor.poglajen@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bojan Vrtovec, MD, PhD</last_name>
      <phone>+3861 522 1157</phone>
      <email>bojan.vrtovec@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Polona Razingar</last_name>
      <email>polona.razingar@kclj.si</email>
    </contact_backup>
    <investigator>
      <last_name>Bojan Vrtovec, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Bojan Vrtovec</investigator_full_name>
    <investigator_title>Medical Director, Advanced Heart Failure and Transplantation Programme</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

